This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 3270 results found since Jan 2013.

Anti-neurofascin 155 Antibody-positive Neuropathy in a Human Immunodeficiency Virus-infected Patient
Intern Med. 2023 Jun 28. doi: 10.2169/internalmedicine.1919-23. Online ahead of print.ABSTRACTHuman immunodeficiency virus (HIV)-associated neuropathy is a common complication of HIV infection and has several clinical subtypes. HIV-associated chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a demyelinating neuropathy whose clinical features are known to differ from those of CIDP in the HIV-uninfected population. We herein report a case of CIDP in an HIV-infected patient who was finally diagnosed with anti-neurofascin 155 (NF155) antibody-positive neuropathy. The clinical features, including clinical find...
Source: Internal Medicine - June 28, 2023 Category: Internal Medicine Authors: So Okubo Tatsuo Mano Atsushi Sudo Ryoji Goto Satoka Yano Manato Hara Hiroyuki Ishiura Wataru Satake Shintaro Yanagimoto Hidenori Ogata Tatsushi Toda Source Type: research

Ultrasound-based radiomic analysis of the peripheral nerves for differentiation between CIDP and POEMS syndrome
CONCLUSION: US-based radiomic analysis has high AUC values in differentiating POEM syndrome from CIDP. Machine-learning algorithms further improved the discriminative ability.PMID:37376758 | DOI:10.1177/02841851231181680
Source: Acta Radiologica - June 28, 2023 Category: Radiology Authors: Jun Hashiba Hajime Yokota Kota Abe Yukari Sekiguchi Shinobu Ikeda Atsuhiko Sugiyama Satoshi Kuwabara Takashi Uno Source Type: research

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study
This report describes the safety findings.MethodsPatients were randomised to receive a 2.0 g/kg induction dose followed by maintenance doses of either 0.5, 1.0 or 2.0 g/kg IVIg every 3 weeks over 24 weeks.ResultsAll 142 enrolled patients were included in the safety analyses. In total, 286 treatment-emergent adverse events (TEAEs) were reported in 89 patients, of which 173 (60.5%) were considered treatment-related. Most TEAEs were of mild severity. Eleven serious TEAEs were reported in 6 patients. Two serious TEAEs in one patient (headache and vomiting) were considered related to treatment, which resolved without study disc...
Source: Drug Safety - June 28, 2023 Category: Drugs & Pharmacology Source Type: research

Chronic inflammatory demyelinating polyradiculoneuropathy in a patient with systemic lupus erythematosus without systemic activity
In conclusion, CIDP in SLE is rare, reported in just 0.2%. Immunosuppressive therapy should be considered whether initial improvement is not evidenced, as seen in our case requiring cyclophosphamide; interestingly, systemic activity was in remission as the peripheral nervous system is not part of neurological compromise, and we suggest evaluating this unusual presentation into rheumatological practice.PMID:37369195 | DOI:10.1177/09612033231186718
Source: Lupus - June 27, 2023 Category: Rheumatology Authors: Omar-Javier Calixto Santiago Poveda Maria Alejandra Meneses-Toro Edward Camilo Vera-Parra Consuelo Romero-S ánchez Luisa Fernanda Guzman Molano Juan Manuel Bello-Gualtero Source Type: research

How I Treat Chronic Inflammatory Demyelinating Polyneuropathy Podcast
AbstractChronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated neuropathy that typically presents with progressive or relapsing, symmetric, proximal, and distal weakness of upper and lower limbs, sensory involvement of at least two limbs, and decreased or absent deep tendon reflexes. The symptoms of CIDP can be similar to those of other neuropathies, making diagnosis difficult, which can often lead to delays in correct diagnosis and treatment. The updated European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021 guideline outlines a set of diagnostic criteria that help to identi...
Source: Neurology and Therapy - June 26, 2023 Category: Neurology Source Type: research

Systematic Comparison of Muscle Ultrasound Thickness in Polyneuropathies and Other Neuromuscular Diseases
ConclusionThe current study shows that muscle ultrasound thickness is not specific in NM disorders, but shows a global reduction in thickness compared with healthy controls after corrections for age and BMI.
Source: Neurology and Therapy - June 20, 2023 Category: Neurology Source Type: research

Chronic inflammatory demyelinating polyradiculoneuropathy in patients with diabetes mellitus - treatment with intravenous immunoglobulins: A systematic review
CONCLUSIONS: Current scientific data do not allow for strong recommendations on the choice of treatment for CIDP. A randomised, multicentre study evaluating the efficacy of different therapeutic approaches to this disease entity needs to be planned.PMID:37290187 | DOI:10.1016/j.biopha.2023.114974
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 8, 2023 Category: Drugs & Pharmacology Authors: Szymon Andrusi ów Zuzanna Pawlak Bart łomiej Stańczykiewicz Katarzyna Bogunia-Kubik Magdalena Koszewicz Source Type: research

RWD22 A Novel Patient-Centered Real-World Evidence Study Designed to Better Understand Chronic Inflammatory Demyelinating Polyneuropathy Using Longitudinal Data in the United States
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune inflammatory disorder of the peripheral nervous system. Evidence is limited with the real-world patient population. The aim of the study is to better understand patient demographics, diagnostic journey, healthcare resource utilization (HCRU) and treatment patterns of patients in the Inspire CIDP cohort using primarily medical claims and user-generated contents.
Source: Value in Health - June 1, 2023 Category: International Medicine & Public Health Authors: D. Kuk, B.P.H. Chen, V. Kudesia, R. Tsai, A. Hoke Source Type: research

A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy
Condition:   Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Intervention:   Drug: Rituximab Sponsor:   Istituto Clinico Humanitas Active, not recruiting
Source: ClinicalTrials.gov - May 26, 2023 Category: Research Source Type: clinical trials